Has Tomas Holmlund, MD received payments from drug or device companies?

Yes. Drug and device makers reported $42,386 in general payments to Tomas Holmlund, MD across 493 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tomas Holmlund, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tomas Holmlund, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tomas Holmlund, MD

Neurology · Amherst, NYNPI 1770644528

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $26,126 of the $42,386 with a category attached, or 61.6%. 56 manufacturers reported payments, led by AbbVie at 37.9% of the total. Reporting peaked in 2019 at $17,756 and has fallen 97.6% since, to $420 in 2025.

$42,386in general payments, 2019–2025

Across 493 payments — averaging $85.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$16K
Tanabe Pharma America, Inc.$11K
AstraZeneca$8K
Teva Pharmaceuticals USA, Inc.$1K
Novartis$832
Avanir Pharmaceuticals, Inc.$591
plus $5K from 50 others

$11,453in research payments, 2019–2025

Across 1 payment — averaging $11,453 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Mitsubishi Tanabe Pharma Development America, Inc.$11K

$95,223in ownership & investment interests, 2019–2025

Across 7 payments — averaging $13,603 each. An ownership or investment interest held by the physician or an immediate family member.

Neurology Practice Consortium GPO, LLC$95K

What the payments were for

Consulting fees$5,65013%
Speaking & faculty fees$26,12662%
Travel & lodging$1,7484%
Food & beverage$8,60220%
Education$2591%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	42	$16,063
Tanabe Pharma America, Inc.	50	$11,354
AstraZeneca(2 entities)	25	$7,693
Teva Pharmaceuticals USA, Inc.	56	$1,003
Novartis	58	$832
Avanir Pharmaceuticals, Inc.	26	$591
Argenx US, Inc.	2	$522
Alnylam Pharmaceuticals Inc.	19	$326
Neurocrine Biosciences, Inc.	18	$271
Adamas Pharmaceuticals, Inc.	12	$262
UCB, Inc.	14	$242
Amgen(2 entities)	8	$230
Acadia Pharmaceuticals Inc	14	$204
Merz North America, Inc.	9	$188
Lundbeck LLC	12	$174
EDW Pharma, Inc.	1	$162
Biogen	8	$152
Greenwich Biosciences, Inc.	10	$144
Biohaven Pharmaceutical Holding Company Ltd.	9	$139
Merz Pharmaceuticals, LLC	3	$133
CSL Behring	6	$122
MDD US Operations, LLC	3	$104
Sanofi-aventis U.S. LLC	5	$103
Sanofi	7	$85
Kyowa Kirin, Inc.	5	$83
Johnson & Johnson	5	$67
Avion Pharmaceuticals	5	$67
SK Life Science, Inc.	3	$64
GE HealthCare	6	$64
Akcea Therapeutics, Inc.	4	$61
EMD Serono, Inc.	3	$56
Lilly USA, LLC	3	$52
Grifols USA, LLC	2	$52
Ipsen Biopharmaceuticals, Inc	3	$51
Sunovion Pharmaceuticals Inc.	2	$51
Catalyst Pharmaceuticals, Inc.	2	$51
Eisai Inc.	2	$50
Genentech USA, Inc.	3	$46
Amneal Pharmaceuticals LLC	3	$46
Upsher-smith Laboratories LLC	2	$44
Acorda Therapeutics, Inc	2	$39
Harmony Biosciences LLC	2	$36
Octapharma USA, Inc.	2	$33
TG Therapeutics, Inc.	2	$32
Bayer	2	$30
Biohaven Pharmaceuticals, Inc.	2	$29
Banner Life Sciences, LLC	2	$28
Jazz Pharmaceuticals Inc.	1	$24
Mallinckrodt Hospital Products Inc.	1	$20
Takeda Pharmaceuticals U.S.A., Inc.	1	$20
Fresenius Kabi USA, LLC	1	$18
Bristol Myers Squibb	1	$17
Bausch Health US, LLC	1	$16
Arbor Pharmaceuticals, Inc.	1	$15
E.r. Squibb & Sons, L.L.C.	1	$14
Philips North America LLC	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$15,600
Radicava$10,347
SOLIRIS$5,228
VYVGART$500
Tiglutik$162

How this compares

$42,386 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York →

Medicare billing

Part B allowed, 2024

$41,141

Medicare patients

134

Services billed

321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Amherst

Nicolas SaikaliAmherst$1.5M
Jennifer McVigeAmherst$982K
Bennett MyersAmherst$432K
Laszlo MechtlerAmherst$347K
Wisam ElmalikAmherst$289K
Idan SharonBrooklyn$2.1M
Allan PerelStaten Island$1.7M
David KreitzmanCommack$1.5M
Charles ArgoffAlbany$1.2M
Stephen KriegerNew York$1.1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →